cmcmaster/pbs_prescribing_texts · Datasets at Hugging Face

prescribing_txt_id int64 6.16k 33.6k	prescribing_type stringclasses 6 values	prescribing_txt stringlengths 6 11k	prscrbg_txt_html stringlengths 13 12.3k	complex_authority_rqrd_ind stringclasses 2 values	assessment_type_code stringclasses 2 values	apply_to_increase_mq_flag stringclasses 2 values	apply_to_increase_nr_flag stringclasses 2 values	schedule_code int64 3.67k 3.67k
6,158	ADMINISTRATIVE_ADVICE	Authorities for increased maximum quantities and/or repeats for the oral forms of diazepam will be granted only for (i) the treatment of disabling spasticity; or (ii) malignant neoplasia (late stage); or (iii) use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal; or (iv) use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal. Up to six months'' treatment (i.e. one month''s treatment with five repeats) may be requested.	<p>Authorities for increased maximum quantities and/or repeats for the oral forms of diazepam will be granted only for </p><blockquote style="MARGIN-RIGHT: 0px"><p>(i) the treatment of disabling spasticity; or</p></blockquote><blockquote style="MARGIN-RIGHT: 0px"><p>(ii) malignant neoplasia (late stage); or</p></blockquote><blockquote style="MARGIN-RIGHT: 0px"><p>(iii) use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal; or</p></blockquote><blockquote style="MARGIN-RIGHT: 0px"><p>(iv) use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal.</p></blockquote><p> Up to six months' treatment (i.e. one month's treatment with five repeats) may be requested.</p>	N	null	N	N	3,671
6,523	ADMINISTRATIVE_ADVICE	For immunisation of adults and children aged greater than or equal to 8 years.	<p>For immunisation of adults and children aged greater than or equal to 8 years.</p>	N	null	N	N	3,671
6,810	ADMINISTRATIVE_ADVICE	Continuing Therapy Only: For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.	<p>Continuing Therapy Only:</p><p> For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.</p>	N	null	N	N	3,671
6,918	CAUTION	There are reports of fatal hepatotoxicity, particularly in children. There is increasing evidence of dose-related teratogenesis from this drug.	<p>There are reports of fatal hepatotoxicity, particularly in children.</p><p> There is increasing evidence of dose-related teratogenesis from this drug.</p>	N	null	N	N	3,671
6,945	CAUTION	Prochlorperazine may be associated with parkinsonism and tardive dyskinesia and should be used for short-term treatment only.	<p>Prochlorperazine may be associated with parkinsonism and tardive dyskinesia and should be used for short-term treatment only.</p>	N	null	N	N	3,671
7,597	INDICATION	Stage IV clear cell variant renal cell carcinoma (RCC)	<p>Stage IV clear cell variant renal cell carcinoma (RCC)</p>	N	null	N	N	3,671
7,600	PARAMETER	Patient must have a WHO performance status of 2 or less	<p>Patient must have a WHO performance status of 2 or less.</p>	N	IMMEDIATE	N	N	3,671
7,601	CRITERIA	Clinical criteria: Patient must have a WHO performance status of 2 or less	<p><b>Clinical criteria:</b></p><ul><li><p>Patient must have a WHO performance status of 2 or less</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,602	PARAMETER	The treatment must be the sole PBS-subsidised tyrosine kinase inhibitor therapy for this condition	<p>The treatment must be the sole PBS-subsidised tyrosine kinase inhibitor therapy for this condition.</p>	N	IMMEDIATE	N	N	3,671
7,603	CRITERIA	Clinical criteria: The treatment must be the sole PBS-subsidised tyrosine kinase inhibitor therapy for this condition	<p><b>Clinical criteria:</b></p><ul><li><p>The treatment must be the sole PBS-subsidised tyrosine kinase inhibitor therapy for this condition</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,604	ADMINISTRATIVE_ADVICE	Patients who have developed intolerance to sunitinib of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised pazopanib.	<p align="justify">Patients who have developed intolerance to sunitinib of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised pazopanib.</p>	N	null	N	N	3,671
7,605	ADMINISTRATIVE_ADVICE	Patients who have progressive disease with pazopanib are no longer eligible for PBS-subsidised pazopanib.	<p>Patients who have progressive disease with pazopanib are no longer eligible for PBS-subsidised pazopanib.</p>	N	null	N	N	3,671
7,606	ADMINISTRATIVE_ADVICE	No increase in the maximum quantity or number of units may be authorised.	<p>No increase in the maximum quantity or number of units may be authorised.</p>	N	null	N	N	3,671
7,607	ADMINISTRATIVE_ADVICE	No increase in the maximum number of repeats may be authorised.	<p>No increase in the maximum number of repeats may be authorised.</p>	N	null	N	N	3,671
7,608	ADMINISTRATIVE_ADVICE	Special Pricing Arrangements apply.	<p align="justify">Special Pricing Arrangements apply.</p>	N	null	N	N	3,671
7,612	PARAMETER	Patient must have stable or responding disease according to the Response Evaluation Criteria In Solid Tumours (RECIST)	<p>Patient must have stable or responding disease according to the Response Evaluation Criteria In Solid Tumours (RECIST).</p>	N	IMMEDIATE	N	N	3,671
7,613	CRITERIA	Clinical criteria: Patient must have stable or responding disease according to the Response Evaluation Criteria In Solid Tumours (RECIST)	<p><b>Clinical criteria:</b></p><ul><li><p>Patient must have stable or responding disease according to the Response Evaluation Criteria In Solid Tumours (RECIST)</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,614	ADMINISTRATIVE_ADVICE	Response Evaluation Criteria In Solid Tumours (RECIST) is defined as follows: Complete response (CR) is disappearance of all target lesions. Partial response (PR) is a 30% decrease in the sum of the longest diameter of target lesions. Progressive disease (PD) is a 20% increase in the sum of the longest diameter of target lesions. Stable disease (SD) is small changes that do not meet above criteria.	<p align="justify">Response Evaluation Criteria In Solid Tumours (RECIST) is defined as follows:</p><p align="justify">Complete response (CR) is disappearance of all target lesions.</p><p align="justify">Partial response (PR) is a 30% decrease in the sum of the longest diameter of target lesions.</p><p align="justify">Progressive disease (PD) is a 20% increase in the sum of the longest diameter of target lesions.</p><p align="justify">Stable disease (SD) is small changes that do not meet above criteria.</p>	N	null	N	N	3,671
7,620	ADMINISTRATIVE_ADVICE	Patients who have developed intolerance to pazopanib of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised sunitinib.	<p align="justify">Patients who have developed intolerance to pazopanib of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised sunitinib.</p>	N	null	N	N	3,671
7,621	ADMINISTRATIVE_ADVICE	Patients who have progressive disease with sunitinib are no longer eligible for PBS-subsidised sunitinib.	<p align="justify">Patients who have progressive disease with sunitinib are no longer eligible for PBS-subsidised sunitinib.</p>	N	null	N	N	3,671
7,646	PARAMETER	The treatment must be in combination with chemotherapy	<p>The treatment must be in combination with chemotherapy.</p>	N	IMMEDIATE	N	N	3,671
7,699	INDICATION	Bone metastases	<p>Bone metastases</p>	N	null	N	N	3,671
7,700	PARAMETER	The condition must be due to breast cancer	<p>The condition must be due to breast cancer.</p>	N	IMMEDIATE	N	N	3,671
7,701	CRITERIA	Clinical criteria: The condition must be due to breast cancer	<p><b>Clinical criteria:</b></p><ul><li><p>The condition must be due to breast cancer</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,703	ADMINISTRATIVE_ADVICE	Continuing Therapy Only: For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.	<p align="justify"><b>Continuing Therapy Only:</b></p><p align="justify">For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners. </p>	N	null	N	N	3,671
7,704	PARAMETER	The condition must be due to castration-resistant prostate cancer	<p>The condition must be due to castration-resistant prostate cancer.</p>	N	IMMEDIATE	N	N	3,671
7,705	CRITERIA	Clinical criteria: The condition must be due to castration-resistant prostate cancer	<p><b>Clinical criteria:</b></p><ul><li><p>The condition must be due to castration-resistant prostate cancer</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,707	INDICATION	Pernicious anaemia	<p>Pernicious anaemia</p>	N	null	N	N	3,671
7,708	ADMINISTRATIVE_ADVICE	One injection of hydroxocobalamin 1 mg every three months provides appropriate maintenance therapy in vitamin B12 deficiencies.	<p>One injection of hydroxocobalamin 1 mg every three months provides appropriate maintenance therapy in vitamin B<sub>12</sub> deficiencies.</p>	N	null	N	N	3,671
7,709	ADMINISTRATIVE_ADVICE	Pharmaceutical benefits that have the form hydroxocobalamin injection 1 mg (as acetate) in 1 mL and pharmaceutical benefits that have the form hydroxocobalamin injection 1 mg (as chloride) in 1 mL are equivalent for the purposes of substitution.	<p>Pharmaceutical benefits that have the form hydroxocobalamin injection 1 mg (as acetate) in 1 mL and pharmaceutical benefits that have the form hydroxocobalamin injection 1 mg (as chloride) in 1 mL are equivalent for the purposes of substitution.</p>	N	null	N	N	3,671
7,710	INDICATION	Proven vitamin B12 deficiencies other than pernicious anaemia	<p>Proven vitamin B12 deficiencies other than pernicious anaemia</p>	N	null	N	N	3,671
7,711	INDICATION	Anaemias associated with vitamin B12 deficiency	<p>Anaemias associated with vitamin B12 deficiency</p>	N	null	N	N	3,671
7,712	INDICATION	Severe established osteoporosis	<p>Severe established osteoporosis</p>	N	null	N	N	3,671
7,713	PARAMETER	Must be treated by a specialist	<p>Must be treated by a specialist.</p>	N	IMMEDIATE	N	N	3,671
7,714	PARAMETER	Must be treated by a consultant physician	<p>Must be treated by a consultant physician.</p>	N	IMMEDIATE	N	N	3,671
7,715	CRITERIA	Treatment criteria: Must be treated by a specialist; OR Must be treated by a consultant physician	<p><b>Treatment criteria:</b></p><ul><li><p>Must be treated by a specialist; OR</p></li> <li><p>Must be treated by a consultant physician</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,716	PARAMETER	Patient must be at very high risk of fracture	<p>Patient must be at very high risk of fracture.</p>	N	IMMEDIATE	N	N	3,671
7,717	CRITERIA	Clinical criteria: Patient must be at very high risk of fracture	<p><b>Clinical criteria:</b></p><ul><li><p>Patient must be at very high risk of fracture</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,718	PARAMETER	Patient must have a bone mineral density (BMD) T-score of -3.0 or less	<p>Patient must have a bone mineral density (BMD) T-score of -3.0 or less.</p>	N	IMMEDIATE	N	N	3,671
7,719	CRITERIA	Clinical criteria: Patient must have a bone mineral density (BMD) T-score of -3.0 or less	<p><b>Clinical criteria:</b></p><ul><li><p>Patient must have a bone mineral density (BMD) T-score of -3.0 or less</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,720	PARAMETER	Patient must have had 2 or more fractures due to minimal trauma	<p>Patient must have had 2 or more fractures due to minimal trauma.</p>	N	IMMEDIATE	N	N	3,671
7,721	CRITERIA	Clinical criteria: Patient must have had 2 or more fractures due to minimal trauma	<p><b>Clinical criteria:</b></p><ul><li><p>Patient must have had 2 or more fractures due to minimal trauma</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,722	PARAMETER	Patient must have experienced at least 1 symptomatic new fracture after at least 12 months continuous therapy with an anti-resorptive agent at adequate doses	<p>Patient must have experienced at least 1 symptomatic new fracture after at least 12 months continuous therapy with an anti-resorptive agent at adequate doses.</p>	N	IMMEDIATE	N	N	3,671
7,723	CRITERIA	Clinical criteria: Patient must have experienced at least 1 symptomatic new fracture after at least 12 months continuous therapy with an anti-resorptive agent at adequate doses	<p><b>Clinical criteria:</b></p><ul><li><p>Patient must have experienced at least 1 symptomatic new fracture after at least 12 months continuous therapy with an anti-resorptive agent at adequate doses</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,726	PARAMETER	The treatment must not exceed a lifetime maximum of 18 months therapy	<p>The treatment must not exceed a lifetime maximum of 18 months therapy.</p>	N	IMMEDIATE	N	N	3,671
7,727	CRITERIA	Clinical criteria: The treatment must not exceed a lifetime maximum of 18 months therapy	<p><b>Clinical criteria:</b></p><ul><li><p>The treatment must not exceed a lifetime maximum of 18 months therapy</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,729	PRESCRIBING_INSTRUCTIONS	A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.	<p>A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.</p>	N	IMMEDIATE	N	N	3,671
7,733	PRESCRIBING_INSTRUCTIONS	Details of prior anti-resorptive therapy, fracture history including the date(s), site(s), the symptoms associated with the fracture(s) which developed after at least 12 months continuous anti-resorptive therapy and the score of the qualifying BMD measurement must be provided at the time of application.	<p align="justify">Details of prior anti-resorptive therapy, fracture history including the date(s), site(s), the symptoms associated with the fracture(s) which developed after at least 12 months continuous anti-resorptive therapy and the score of the qualifying BMD measurement must be provided at the time of application. </p>	N	IMMEDIATE	N	N	3,671
7,735	PARAMETER	Must be treated by a specialist	<p>Must be treated by a specialist.</p>	N	IMMEDIATE	N	N	3,671
7,736	CRITERIA	Treatment criteria: Must be treated by a specialist; OR Must be treated by a consultant physician	<p><b>Treatment criteria:</b></p><ul><li><p>Must be treated by a specialist; OR</p></li> <li><p>Must be treated by a consultant physician</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,737	PARAMETER	Patient must have previously been issued with an authority prescription for this drug	<p>Patient must have previously been issued with an authority prescription for this drug.</p>	N	IMMEDIATE	N	N	3,671
7,738	CRITERIA	Clinical criteria: Patient must have previously been issued with an authority prescription for this drug	<p><b>Clinical criteria:</b></p><ul><li><p>Patient must have previously been issued with an authority prescription for this drug</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,740	ADMINISTRATIVE_ADVICE	Up to a maximum of 18 pens will be reimbursed through the PBS.	<p>Up to a maximum of 18 pens will be reimbursed through the PBS. </p>	N	null	N	N	3,671
7,744	PARAMETER	The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure	<p>The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure.</p>	N	IMMEDIATE	N	N	3,671
7,745	CRITERIA	Clinical criteria: The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure	<p><b>Clinical criteria:</b></p><ul><li><p>The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,746	PARAMETER	Patient must not receive more than 52 weeks of combined PBS-subsidised and non-PBS-subsidised therapy	<p>Patient must not receive more than 52 weeks of combined PBS-subsidised and non-PBS-subsidised therapy.</p>	N	IMMEDIATE	N	N	3,671
7,749	PRESCRIBING_INSTRUCTIONS	HER2 positivity must be demonstrated by in situ hybridisation (ISH).	<p align="justify">HER2 positivity must be demonstrated by in situ hybridisation (ISH).</p>	N	IMMEDIATE	N	N	3,671
7,753	ADMINISTRATIVE_ADVICE	Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at www.servicesaustralia.gov.au Applications for authority to prescribe should be submitted online using the form upload facility in Health Professional Online Services (HPOS) at www.servicesaustralia.gov.au/hpos Or mailed to: Services Australia Complex Drugs Reply Paid 9826 HOBART TAS 7001	<p align="justify">Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</p><p align="justify">Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at www.servicesaustralia.gov.au</p><p align="justify">Applications for authority to prescribe should be submitted online using the form upload facility in Health Professional Online Services (HPOS) at www.servicesaustralia.gov.au/hpos</p><p align="justify">Or mailed to:</p><p align="justify">Services Australia</p><p align="justify">Complex Drugs</p><p align="justify">Reply Paid 9826</p><p align="justify">HOBART TAS 7001</p>	Y	null	N	N	3,671
7,754	INDICATION	Early HER2 positive breast cancer	<p>Early HER2 positive breast cancer</p>	N	null	N	N	3,671
7,767	ADMINISTRATIVE_ADVICE	Authority applications for continuing treatment may be made by telephone to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).	<p align="justify">Authority applications for continuing treatment may be made by telephone to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</p>	Y	null	N	N	3,671
7,771	INDICATION	Prophylaxis of renal allograft rejection	<p>Prophylaxis of renal allograft rejection</p>	N	null	N	N	3,671
7,772	PARAMETER	The treatment must be under the supervision and direction of a transplant unit	<p>The treatment must be under the supervision and direction of a transplant unit.</p>	N	IMMEDIATE	N	N	3,671
7,773	CRITERIA	Clinical criteria: The treatment must be under the supervision and direction of a transplant unit	<p><b>Clinical criteria:</b></p><ul><li><p>The treatment must be under the supervision and direction of a transplant unit</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,775	ADMINISTRATIVE_ADVICE	Management includes initiation, stabilisation and review of therapy as required.	<p>Management includes initiation, stabilisation and review of therapy as required.</p>	N	null	N	N	3,671
7,776	CAUTION	Careful monitoring of patients is mandatory.	<p>Careful monitoring of patients is mandatory.</p>	N	null	N	N	3,671
7,777	INDICATION	WHO Class III, IV or V lupus nephritis	<p>WHO Class III, IV or V lupus nephritis</p>	N	null	N	N	3,671
7,778	PARAMETER	The condition must be proven by biopsy	<p>The condition must be proven by biopsy.</p>	N	IMMEDIATE	N	N	3,671
7,779	CRITERIA	Clinical criteria: The condition must be proven by biopsy	<p><b>Clinical criteria:</b></p><ul><li><p>The condition must be proven by biopsy</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,780	PARAMETER	Must be treated by a nephrologist or in consultation with a nephrologist	<p>Must be treated by a nephrologist or in consultation with a nephrologist.</p>	N	IMMEDIATE	N	N	3,671
7,781	CRITERIA	Treatment criteria: Must be treated by a nephrologist or in consultation with a nephrologist	<p><b>Treatment criteria:</b></p><ul><li><p>Must be treated by a nephrologist or in consultation with a nephrologist</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,783	PRESCRIBING_INSTRUCTIONS	The name of the consulting nephrologist must be included in the patient medical records.	<p align="justify">The name of the consulting nephrologist must be included in the patient medical records.</p>	N	IMMEDIATE	N	N	3,671
7,791	PARAMETER	The treatment must be in conjunction with dietary therapy and exercise	<p>The treatment must be in conjunction with dietary therapy and exercise.</p>	N	IMMEDIATE	N	N	3,671
7,792	CRITERIA	Clinical criteria: The treatment must be in conjunction with dietary therapy and exercise	<p><b>Clinical criteria:</b></p><ul><li><p>The treatment must be in conjunction with dietary therapy and exercise</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,811	INDICATION	Peptic ulcer	<p>Peptic ulcer</p>	N	null	N	N	3,671
7,813	ADMINISTRATIVE_ADVICE	Pharmaceutical benefits that have the forms omeprazole tablet 20 mg, omeprazole capsule 20 mg and omeprazole tablet 20 mg (as magnesium) are equivalent for the purposes of substitution.	<p align="justify">Pharmaceutical benefits that have the forms omeprazole tablet 20 mg, omeprazole capsule 20 mg and omeprazole tablet 20 mg (as magnesium) are equivalent for the purposes of substitution.</p>	N	null	N	N	3,671
7,814	INDICATION	Gastro-oesophageal reflux disease	<p>Gastro-oesophageal reflux disease</p>	N	null	N	N	3,671
7,815	INDICATION	Scleroderma oesophagus	<p>Scleroderma oesophagus</p>	N	null	N	N	3,671
7,816	INDICATION	Zollinger-Ellison syndrome	<p>Zollinger-Ellison syndrome</p>	N	null	N	N	3,671
7,840	PRESCRIBING_INSTRUCTIONS	A clinically important product-related adverse event is defined as follows: (i) Severe myalgia (muscle symptoms without creatine kinase elevation) which is proven to be temporally associated with statin treatment; or (ii) Myositis (clinically important creatine kinase elevation, with or without muscle symptoms) demonstrated by results twice the upper limit of normal on a single reading or a rising pattern on consecutive measurements and which is unexplained by other causes; or (iii) Unexplained, persistent elevations of serum transaminases (greater than 3 times the upper limit of normal) during treatment with a statin.	<p align="justify">A clinically important product-related adverse event is defined as follows: </p><p align="justify">(i) Severe myalgia (muscle symptoms without creatine kinase elevation) which is proven to be temporally associated with statin treatment; or </p><p align="justify">(ii) Myositis (clinically important creatine kinase elevation, with or without muscle symptoms) demonstrated by results twice the upper limit of normal on a single reading or a rising pattern on consecutive measurements and which is unexplained by other causes; or </p><p align="justify">(iii) Unexplained, persistent elevations of serum transaminases (greater than 3 times the upper limit of normal) during treatment with a statin.</p>	N	IMMEDIATE	N	N	3,671
7,841	INDICATION	For a patient who is unable to take a solid dose form of atenolol.	<p>For a patient who is unable to take a solid dose form of atenolol.</p>	N	null	N	N	3,671
7,842	INDICATION	Nausea and vomiting	<p>Nausea and vomiting</p>	N	null	N	N	3,671
7,843	PARAMETER	The condition must be associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration	<p>The condition must be associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p>	N	IMMEDIATE	N	N	3,671
7,844	CRITERIA	Clinical criteria: The condition must be associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration	<p><b>Clinical criteria:</b></p><ul><li><p>The condition must be associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,846	PRESCRIBING_INSTRUCTIONS	Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle.	<p align="justify">Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle.</p>	N	IMMEDIATE	Y	N	3,671
7,847	PARAMETER	The condition must be associated with radiotherapy being used to treat malignancy	<p>The condition must be associated with radiotherapy being used to treat malignancy.</p>	N	IMMEDIATE	N	N	3,671
7,848	CRITERIA	Clinical criteria: The condition must be associated with radiotherapy being used to treat malignancy	<p><b>Clinical criteria:</b></p><ul><li><p>The condition must be associated with radiotherapy being used to treat malignancy</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,850	ADMINISTRATIVE_ADVICE	Molnlycke Health Care products are distributed through leading pharmacy distributors. To best ensure product availability at the RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email: [email protected]. Molnlycke Health Care is not able to ensure product availability or pricing on listed products beyond these two suppliers.	<p align="justify">Molnlycke Health Care products are distributed through leading pharmacy distributors. To best ensure product availability at the RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email: <u>[email protected]</u>. Molnlycke Health Care is not able to ensure product availability or pricing on listed products beyond these two suppliers.</p>	N	null	N	N	3,671
7,851	INDICATION	Chronic arthropathies (including osteoarthritis)	<p>Chronic arthropathies (including osteoarthritis)</p>	N	null	N	N	3,671
7,852	PARAMETER	The condition must have an inflammatory component	<p>The condition must have an inflammatory component.</p>	N	IMMEDIATE	N	N	3,671
7,853	CRITERIA	Clinical criteria: The condition must have an inflammatory component	<p><b>Clinical criteria:</b></p><ul><li><p>The condition must have an inflammatory component</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,854	PARAMETER	Patient must be unable to take a solid dose form of a non-steroidal anti-inflammatory agent	<p>Patient must be unable to take a solid dose form of a non-steroidal anti-inflammatory agent.</p>	N	IMMEDIATE	N	N	3,671
7,855	CRITERIA	Clinical criteria: Patient must be unable to take a solid dose form of a non-steroidal anti-inflammatory agent	<p><b>Clinical criteria:</b></p><ul><li><p>Patient must be unable to take a solid dose form of a non-steroidal anti-inflammatory agent</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,857	INDICATION	Bone pain	<p>Bone pain</p>	N	null	N	N	3,671
7,858	PARAMETER	The condition must be due to malignant disease	<p>The condition must be due to malignant disease.</p>	N	IMMEDIATE	N	N	3,671
7,859	CRITERIA	Clinical criteria: The condition must be due to malignant disease	<p><b>Clinical criteria:</b></p><ul><li><p>The condition must be due to malignant disease</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,861	INDICATION	Severe pain	<p>Severe pain</p>	N	null	N	N	3,671
7,862	PARAMETER	Patient must be undergoing palliative care	<p>Patient must be undergoing palliative care.</p>	N	IMMEDIATE	N	N	3,671
7,863	CRITERIA	Treatment criteria: Patient must be undergoing palliative care	<p><b>Treatment criteria:</b></p><ul><li><p>Patient must be undergoing palliative care</p></li></ul>	N	IMMEDIATE	N	N	3,671
7,869	INDICATION	Severe dry eye syndrome	<p>Severe dry eye syndrome</p>	N	null	N	N	3,671
7,874	PARAMETER	Patient must be sensitive to preservatives in multi-dose eye drops	<p>Patient must be sensitive to preservatives in multi-dose eye drops.</p>	N	IMMEDIATE	N	N	3,671

6,158

ADMINISTRATIVE_ADVICE

Authorities for increased maximum quantities and/or repeats for the oral forms of diazepam will be granted only for (i) the treatment of disabling spasticity; or (ii) malignant neoplasia (late stage); or (iii) use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal; or (iv) use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal. Up to six months'' treatment (i.e. one month''s treatment with five repeats) may be requested.

Authorities for increased maximum quantities and/or repeats for the oral forms of diazepam will be granted only for <blockquote style="MARGIN-RIGHT: 0px">(i) the treatment of disabling spasticity; or</blockquote><blockquote style="MARGIN-RIGHT: 0px">(ii) malignant neoplasia (late stage); or</blockquote><blockquote style="MARGIN-RIGHT: 0px">(iii) use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal; or</blockquote><blockquote style="MARGIN-RIGHT: 0px">(iv) use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal.</blockquote> Up to six months' treatment (i.e. one month's treatment with five repeats) may be requested.

N

null

N

3,671

6,523

ADMINISTRATIVE_ADVICE

For immunisation of adults and children aged greater than or equal to 8 years.

For immunisation of adults and children aged greater than or equal to 8 years.

N

null

N

3,671

6,810

ADMINISTRATIVE_ADVICE

Continuing Therapy Only: For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Continuing Therapy Only: For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

N

null

N

3,671

6,918

CAUTION

There are reports of fatal hepatotoxicity, particularly in children. There is increasing evidence of dose-related teratogenesis from this drug.

There are reports of fatal hepatotoxicity, particularly in children. There is increasing evidence of dose-related teratogenesis from this drug.

N

null

N

3,671

6,945

CAUTION

Prochlorperazine may be associated with parkinsonism and tardive dyskinesia and should be used for short-term treatment only.

Prochlorperazine may be associated with parkinsonism and tardive dyskinesia and should be used for short-term treatment only.

N

null

N

3,671

7,597

INDICATION

Stage IV clear cell variant renal cell carcinoma (RCC)

Stage IV clear cell variant renal cell carcinoma (RCC)

N

null

N

3,671

7,600

PARAMETER

Patient must have a WHO performance status of 2 or less

Patient must have a WHO performance status of 2 or less.

N

IMMEDIATE

N

3,671

7,601

CRITERIA

Clinical criteria: Patient must have a WHO performance status of 2 or less

Clinical criteria:<ul><li>Patient must have a WHO performance status of 2 or less</li></ul>

N

IMMEDIATE

N

3,671

7,602

PARAMETER

The treatment must be the sole PBS-subsidised tyrosine kinase inhibitor therapy for this condition

The treatment must be the sole PBS-subsidised tyrosine kinase inhibitor therapy for this condition.

N

IMMEDIATE

N

3,671

7,603

CRITERIA

Clinical criteria: The treatment must be the sole PBS-subsidised tyrosine kinase inhibitor therapy for this condition

Clinical criteria:<ul><li>The treatment must be the sole PBS-subsidised tyrosine kinase inhibitor therapy for this condition</li></ul>

N

IMMEDIATE

N

3,671

7,604

ADMINISTRATIVE_ADVICE

Patients who have developed intolerance to sunitinib of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised pazopanib.

Patients who have developed intolerance to sunitinib of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised pazopanib.

N

null

N

3,671

7,605

ADMINISTRATIVE_ADVICE

Patients who have progressive disease with pazopanib are no longer eligible for PBS-subsidised pazopanib.

Patients who have progressive disease with pazopanib are no longer eligible for PBS-subsidised pazopanib.

N

null

N

3,671

7,606

ADMINISTRATIVE_ADVICE

No increase in the maximum quantity or number of units may be authorised.

No increase in the maximum quantity or number of units may be authorised.

N

null

N

3,671

7,607

ADMINISTRATIVE_ADVICE

No increase in the maximum number of repeats may be authorised.

No increase in the maximum number of repeats may be authorised.

N

null

N

3,671

7,608

ADMINISTRATIVE_ADVICE

Special Pricing Arrangements apply.

Special Pricing Arrangements apply.

N

null

N

3,671

7,612

PARAMETER

Patient must have stable or responding disease according to the Response Evaluation Criteria In Solid Tumours (RECIST)

Patient must have stable or responding disease according to the Response Evaluation Criteria In Solid Tumours (RECIST).

N

IMMEDIATE

N

3,671

7,613

CRITERIA

Clinical criteria: Patient must have stable or responding disease according to the Response Evaluation Criteria In Solid Tumours (RECIST)

Clinical criteria:<ul><li>Patient must have stable or responding disease according to the Response Evaluation Criteria In Solid Tumours (RECIST)</li></ul>

N

IMMEDIATE

N

3,671

7,614

ADMINISTRATIVE_ADVICE

Response Evaluation Criteria In Solid Tumours (RECIST) is defined as follows: Complete response (CR) is disappearance of all target lesions. Partial response (PR) is a 30% decrease in the sum of the longest diameter of target lesions. Progressive disease (PD) is a 20% increase in the sum of the longest diameter of target lesions. Stable disease (SD) is small changes that do not meet above criteria.

Response Evaluation Criteria In Solid Tumours (RECIST) is defined as follows:Complete response (CR) is disappearance of all target lesions.Partial response (PR) is a 30% decrease in the sum of the longest diameter of target lesions.Progressive disease (PD) is a 20% increase in the sum of the longest diameter of target lesions.Stable disease (SD) is small changes that do not meet above criteria.

N

null

N

3,671

7,620

ADMINISTRATIVE_ADVICE

Patients who have developed intolerance to pazopanib of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised sunitinib.

Patients who have developed intolerance to pazopanib of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised sunitinib.

N

null

N

3,671

7,621

ADMINISTRATIVE_ADVICE

Patients who have progressive disease with sunitinib are no longer eligible for PBS-subsidised sunitinib.

Patients who have progressive disease with sunitinib are no longer eligible for PBS-subsidised sunitinib.

N

null

N

3,671

7,646

PARAMETER

The treatment must be in combination with chemotherapy

The treatment must be in combination with chemotherapy.

N

IMMEDIATE

N

3,671

7,699

INDICATION

Bone metastases

Bone metastases

N

null

N

3,671

7,700

PARAMETER

The condition must be due to breast cancer

The condition must be due to breast cancer.

N

IMMEDIATE

N

3,671

7,701

CRITERIA

Clinical criteria: The condition must be due to breast cancer

Clinical criteria:<ul><li>The condition must be due to breast cancer</li></ul>

N

IMMEDIATE

N

3,671

7,703

ADMINISTRATIVE_ADVICE

Continuing Therapy Only: For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Continuing Therapy Only:For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.

N

null

N

3,671

7,704

PARAMETER

The condition must be due to castration-resistant prostate cancer

The condition must be due to castration-resistant prostate cancer.

N

IMMEDIATE

N

3,671

7,705

CRITERIA

Clinical criteria: The condition must be due to castration-resistant prostate cancer

Clinical criteria:<ul><li>The condition must be due to castration-resistant prostate cancer</li></ul>

N

IMMEDIATE

N

3,671

7,707

INDICATION

Pernicious anaemia

Pernicious anaemia

N

null

N

3,671

7,708

ADMINISTRATIVE_ADVICE

One injection of hydroxocobalamin 1 mg every three months provides appropriate maintenance therapy in vitamin B12 deficiencies.

One injection of hydroxocobalamin 1 mg every three months provides appropriate maintenance therapy in vitamin B12 deficiencies.

N

null

N

3,671

7,709

ADMINISTRATIVE_ADVICE

Pharmaceutical benefits that have the form hydroxocobalamin injection 1 mg (as acetate) in 1 mL and pharmaceutical benefits that have the form hydroxocobalamin injection 1 mg (as chloride) in 1 mL are equivalent for the purposes of substitution.

Pharmaceutical benefits that have the form hydroxocobalamin injection 1 mg (as acetate) in 1 mL and pharmaceutical benefits that have the form hydroxocobalamin injection 1 mg (as chloride) in 1 mL are equivalent for the purposes of substitution.

N

null

N

3,671

7,710

INDICATION

Proven vitamin B12 deficiencies other than pernicious anaemia

Proven vitamin B12 deficiencies other than pernicious anaemia

N

null

N

3,671

7,711

INDICATION

Anaemias associated with vitamin B12 deficiency

Anaemias associated with vitamin B12 deficiency

N

null

N

3,671

7,712

INDICATION

Severe established osteoporosis

Severe established osteoporosis

N

null

N

3,671

7,713

PARAMETER

Must be treated by a specialist

Must be treated by a specialist.

N

IMMEDIATE

N

3,671

7,714

PARAMETER

Must be treated by a consultant physician

Must be treated by a consultant physician.

N

IMMEDIATE

N

3,671

7,715

CRITERIA

Treatment criteria: Must be treated by a specialist; OR Must be treated by a consultant physician

Treatment criteria:<ul><li>Must be treated by a specialist; OR</li> <li>Must be treated by a consultant physician</li></ul>

N

IMMEDIATE

N

3,671

7,716

PARAMETER

Patient must be at very high risk of fracture

Patient must be at very high risk of fracture.

N

IMMEDIATE

N

3,671

7,717

CRITERIA

Clinical criteria: Patient must be at very high risk of fracture

Clinical criteria:<ul><li>Patient must be at very high risk of fracture</li></ul>

N

IMMEDIATE

N

3,671

7,718

PARAMETER

Patient must have a bone mineral density (BMD) T-score of -3.0 or less

Patient must have a bone mineral density (BMD) T-score of -3.0 or less.

N

IMMEDIATE

N

3,671

7,719

CRITERIA

Clinical criteria: Patient must have a bone mineral density (BMD) T-score of -3.0 or less

Clinical criteria:<ul><li>Patient must have a bone mineral density (BMD) T-score of -3.0 or less</li></ul>

N

IMMEDIATE

N

3,671

7,720

PARAMETER

Patient must have had 2 or more fractures due to minimal trauma

Patient must have had 2 or more fractures due to minimal trauma.

N

IMMEDIATE

N

3,671

7,721

CRITERIA

Clinical criteria: Patient must have had 2 or more fractures due to minimal trauma

Clinical criteria:<ul><li>Patient must have had 2 or more fractures due to minimal trauma</li></ul>

N

IMMEDIATE

N

3,671

7,722

PARAMETER

Patient must have experienced at least 1 symptomatic new fracture after at least 12 months continuous therapy with an anti-resorptive agent at adequate doses

Patient must have experienced at least 1 symptomatic new fracture after at least 12 months continuous therapy with an anti-resorptive agent at adequate doses.

N

IMMEDIATE

N

3,671

7,723

CRITERIA

Clinical criteria: Patient must have experienced at least 1 symptomatic new fracture after at least 12 months continuous therapy with an anti-resorptive agent at adequate doses

Clinical criteria:<ul><li>Patient must have experienced at least 1 symptomatic new fracture after at least 12 months continuous therapy with an anti-resorptive agent at adequate doses</li></ul>

N

IMMEDIATE

N

3,671

7,726

PARAMETER

The treatment must not exceed a lifetime maximum of 18 months therapy

The treatment must not exceed a lifetime maximum of 18 months therapy.

N

IMMEDIATE

N

3,671

7,727

CRITERIA

Clinical criteria: The treatment must not exceed a lifetime maximum of 18 months therapy

Clinical criteria:<ul><li>The treatment must not exceed a lifetime maximum of 18 months therapy</li></ul>

N

IMMEDIATE

N

3,671

7,729

PRESCRIBING_INSTRUCTIONS

A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

N

IMMEDIATE

N

3,671

7,733

PRESCRIBING_INSTRUCTIONS

Details of prior anti-resorptive therapy, fracture history including the date(s), site(s), the symptoms associated with the fracture(s) which developed after at least 12 months continuous anti-resorptive therapy and the score of the qualifying BMD measurement must be provided at the time of application.

Details of prior anti-resorptive therapy, fracture history including the date(s), site(s), the symptoms associated with the fracture(s) which developed after at least 12 months continuous anti-resorptive therapy and the score of the qualifying BMD measurement must be provided at the time of application.

N

IMMEDIATE

N

3,671

7,735

PARAMETER

Must be treated by a specialist

Must be treated by a specialist.

N

IMMEDIATE

N

3,671

7,736

CRITERIA

Treatment criteria: Must be treated by a specialist; OR Must be treated by a consultant physician

Treatment criteria:<ul><li>Must be treated by a specialist; OR</li> <li>Must be treated by a consultant physician</li></ul>

N

IMMEDIATE

N

3,671

7,737

PARAMETER

Patient must have previously been issued with an authority prescription for this drug

Patient must have previously been issued with an authority prescription for this drug.

N

IMMEDIATE

N

3,671

7,738

CRITERIA

Clinical criteria: Patient must have previously been issued with an authority prescription for this drug

Clinical criteria:<ul><li>Patient must have previously been issued with an authority prescription for this drug</li></ul>

N

IMMEDIATE

N

3,671

7,740

ADMINISTRATIVE_ADVICE

Up to a maximum of 18 pens will be reimbursed through the PBS.

Up to a maximum of 18 pens will be reimbursed through the PBS.

N

null

N

3,671

7,744

PARAMETER

The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure

The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure.

N

IMMEDIATE

N

3,671

7,745

CRITERIA

Clinical criteria: The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure

Clinical criteria:<ul><li>The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure</li></ul>

N

IMMEDIATE

N

3,671

7,746

PARAMETER

Patient must not receive more than 52 weeks of combined PBS-subsidised and non-PBS-subsidised therapy

Patient must not receive more than 52 weeks of combined PBS-subsidised and non-PBS-subsidised therapy.

N

IMMEDIATE

N

3,671

7,749

PRESCRIBING_INSTRUCTIONS

HER2 positivity must be demonstrated by in situ hybridisation (ISH).

HER2 positivity must be demonstrated by in situ hybridisation (ISH).

N

IMMEDIATE

N

3,671

7,753

ADMINISTRATIVE_ADVICE

Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at www.servicesaustralia.gov.au Applications for authority to prescribe should be submitted online using the form upload facility in Health Professional Online Services (HPOS) at www.servicesaustralia.gov.au/hpos Or mailed to: Services Australia Complex Drugs Reply Paid 9826 HOBART TAS 7001

Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at www.servicesaustralia.gov.auApplications for authority to prescribe should be submitted online using the form upload facility in Health Professional Online Services (HPOS) at www.servicesaustralia.gov.au/hposOr mailed to:Services AustraliaComplex DrugsReply Paid 9826HOBART TAS 7001

Y

null

N

3,671

7,754

INDICATION

Early HER2 positive breast cancer

Early HER2 positive breast cancer

N

null

N

3,671

7,767

ADMINISTRATIVE_ADVICE

Authority applications for continuing treatment may be made by telephone to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Authority applications for continuing treatment may be made by telephone to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Y

null

N

3,671

7,771

INDICATION

Prophylaxis of renal allograft rejection

Prophylaxis of renal allograft rejection

N

null

N

3,671

7,772

PARAMETER

The treatment must be under the supervision and direction of a transplant unit

The treatment must be under the supervision and direction of a transplant unit.

N

IMMEDIATE

N

3,671

7,773

CRITERIA

Clinical criteria: The treatment must be under the supervision and direction of a transplant unit

Clinical criteria:<ul><li>The treatment must be under the supervision and direction of a transplant unit</li></ul>

N

IMMEDIATE

N

3,671

7,775

ADMINISTRATIVE_ADVICE

Management includes initiation, stabilisation and review of therapy as required.

Management includes initiation, stabilisation and review of therapy as required.

N

null

N

3,671

7,776

CAUTION

Careful monitoring of patients is mandatory.

Careful monitoring of patients is mandatory.

N

null

N

3,671

7,777

INDICATION

WHO Class III, IV or V lupus nephritis

WHO Class III, IV or V lupus nephritis

N

null

N

3,671

7,778

PARAMETER

The condition must be proven by biopsy

The condition must be proven by biopsy.

N

IMMEDIATE

N

3,671

7,779

CRITERIA

Clinical criteria: The condition must be proven by biopsy

Clinical criteria:<ul><li>The condition must be proven by biopsy</li></ul>

N

IMMEDIATE

N

3,671

7,780

PARAMETER

Must be treated by a nephrologist or in consultation with a nephrologist

Must be treated by a nephrologist or in consultation with a nephrologist.

N

IMMEDIATE

N

3,671

7,781

CRITERIA

Treatment criteria: Must be treated by a nephrologist or in consultation with a nephrologist

Treatment criteria:<ul><li>Must be treated by a nephrologist or in consultation with a nephrologist</li></ul>

N

IMMEDIATE

N

3,671

7,783

PRESCRIBING_INSTRUCTIONS

The name of the consulting nephrologist must be included in the patient medical records.

The name of the consulting nephrologist must be included in the patient medical records.

N

IMMEDIATE

N

3,671

7,791

PARAMETER

The treatment must be in conjunction with dietary therapy and exercise

The treatment must be in conjunction with dietary therapy and exercise.

N

IMMEDIATE

N

3,671

7,792

CRITERIA

Clinical criteria: The treatment must be in conjunction with dietary therapy and exercise

Clinical criteria:<ul><li>The treatment must be in conjunction with dietary therapy and exercise</li></ul>

N

IMMEDIATE

N

3,671

7,811

INDICATION

Peptic ulcer

Peptic ulcer

N

null

N

3,671

7,813

ADMINISTRATIVE_ADVICE

Pharmaceutical benefits that have the forms omeprazole tablet 20 mg, omeprazole capsule 20 mg and omeprazole tablet 20 mg (as magnesium) are equivalent for the purposes of substitution.

Pharmaceutical benefits that have the forms omeprazole tablet 20 mg, omeprazole capsule 20 mg and omeprazole tablet 20 mg (as magnesium) are equivalent for the purposes of substitution.

N

null

N

3,671

7,814

INDICATION

Gastro-oesophageal reflux disease

Gastro-oesophageal reflux disease

N

null

N

3,671

7,815

INDICATION

Scleroderma oesophagus

Scleroderma oesophagus

N

null

N

3,671

7,816

INDICATION

Zollinger-Ellison syndrome

Zollinger-Ellison syndrome

N

null

N

3,671

7,840

PRESCRIBING_INSTRUCTIONS

A clinically important product-related adverse event is defined as follows: (i) Severe myalgia (muscle symptoms without creatine kinase elevation) which is proven to be temporally associated with statin treatment; or (ii) Myositis (clinically important creatine kinase elevation, with or without muscle symptoms) demonstrated by results twice the upper limit of normal on a single reading or a rising pattern on consecutive measurements and which is unexplained by other causes; or (iii) Unexplained, persistent elevations of serum transaminases (greater than 3 times the upper limit of normal) during treatment with a statin.

A clinically important product-related adverse event is defined as follows: (i) Severe myalgia (muscle symptoms without creatine kinase elevation) which is proven to be temporally associated with statin treatment; or (ii) Myositis (clinically important creatine kinase elevation, with or without muscle symptoms) demonstrated by results twice the upper limit of normal on a single reading or a rising pattern on consecutive measurements and which is unexplained by other causes; or (iii) Unexplained, persistent elevations of serum transaminases (greater than 3 times the upper limit of normal) during treatment with a statin.

N

IMMEDIATE

N

3,671

7,841

INDICATION

For a patient who is unable to take a solid dose form of atenolol.

For a patient who is unable to take a solid dose form of atenolol.

N

null

N

3,671

7,842

INDICATION

Nausea and vomiting

Nausea and vomiting

N

null

N

3,671

7,843

PARAMETER

The condition must be associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration

The condition must be associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.

N

IMMEDIATE

N

3,671

7,844

CRITERIA

Clinical criteria: The condition must be associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration

Clinical criteria:<ul><li>The condition must be associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration</li></ul>

N

IMMEDIATE

N

3,671

7,846

PRESCRIBING_INSTRUCTIONS

Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle.

Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle.

N

IMMEDIATE

Y

N

3,671

7,847

PARAMETER

The condition must be associated with radiotherapy being used to treat malignancy

The condition must be associated with radiotherapy being used to treat malignancy.

N

IMMEDIATE

N

3,671

7,848

CRITERIA

Clinical criteria: The condition must be associated with radiotherapy being used to treat malignancy

Clinical criteria:<ul><li>The condition must be associated with radiotherapy being used to treat malignancy</li></ul>

N

IMMEDIATE

N

3,671

7,850

ADMINISTRATIVE_ADVICE

Molnlycke Health Care products are distributed through leading pharmacy distributors. To best ensure product availability at the RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email: [email protected]. Molnlycke Health Care is not able to ensure product availability or pricing on listed products beyond these two suppliers.

Molnlycke Health Care products are distributed through leading pharmacy distributors. To best ensure product availability at the RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email: [email protected]. Molnlycke Health Care is not able to ensure product availability or pricing on listed products beyond these two suppliers.

N

null

N

3,671

7,851

INDICATION

Chronic arthropathies (including osteoarthritis)

Chronic arthropathies (including osteoarthritis)

N

null

N

3,671

7,852

PARAMETER

The condition must have an inflammatory component

The condition must have an inflammatory component.

N

IMMEDIATE

N

3,671

7,853

CRITERIA

Clinical criteria: The condition must have an inflammatory component

Clinical criteria:<ul><li>The condition must have an inflammatory component</li></ul>

N

IMMEDIATE

N

3,671

7,854

PARAMETER

Patient must be unable to take a solid dose form of a non-steroidal anti-inflammatory agent

Patient must be unable to take a solid dose form of a non-steroidal anti-inflammatory agent.

N

IMMEDIATE

N

3,671

7,855

CRITERIA

Clinical criteria: Patient must be unable to take a solid dose form of a non-steroidal anti-inflammatory agent

Clinical criteria:<ul><li>Patient must be unable to take a solid dose form of a non-steroidal anti-inflammatory agent</li></ul>

N

IMMEDIATE

N

3,671

7,857

INDICATION

Bone pain

Bone pain

N

null

N

3,671

7,858

PARAMETER

The condition must be due to malignant disease

The condition must be due to malignant disease.

N

IMMEDIATE

N

3,671

7,859

CRITERIA

Clinical criteria: The condition must be due to malignant disease

Clinical criteria:<ul><li>The condition must be due to malignant disease</li></ul>

N

IMMEDIATE

N

3,671

7,861

INDICATION

Severe pain

Severe pain

N

null

N

3,671

7,862

PARAMETER

Patient must be undergoing palliative care

Patient must be undergoing palliative care.

N

IMMEDIATE

N

3,671

7,863

CRITERIA

Treatment criteria: Patient must be undergoing palliative care

Treatment criteria:<ul><li>Patient must be undergoing palliative care</li></ul>

N

IMMEDIATE

N

3,671

7,869

INDICATION

Severe dry eye syndrome

Severe dry eye syndrome

N

null

N

3,671

7,874

PARAMETER

Patient must be sensitive to preservatives in multi-dose eye drops

Patient must be sensitive to preservatives in multi-dose eye drops.

N

IMMEDIATE

N

3,671

Datasets:

cmcmaster
/

pbs_prescribing_texts

Collection including cmcmaster/pbs_prescribing_texts

PBS Datasets